Company Filing History:
Years Active: 2025
Title: Mark Majewski: Innovator in RNAi Therapeutics
Introduction
Mark Majewski is a notable inventor based in Rockton, IL (US). He has made significant contributions to the field of biotechnology, particularly in the development of RNA interference (RNAi) agents. His work focuses on innovative solutions for inhibiting gene expression, which has important implications for treating various diseases.
Latest Patents
Mark Majewski holds a patent for "RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use." This patent describes RNAi agents and compositions that include these agents, aimed at inhibiting the expression of the ALK7 gene. The ALK7 RNAi agents and their conjugates are designed to reduce ALK7 gene expression, which can provide therapeutic benefits for conditions such as obesity, diabetes, and insulin resistance.
Career Highlights
Mark is currently associated with Arrowhead Pharmaceuticals, Inc., where he continues to advance his research in RNAi technologies. His work is pivotal in the development of pharmaceutical compositions that incorporate ALK7 RNAi agents, potentially leading to new treatment options for patients.
Collaborations
Throughout his career, Mark has collaborated with talented professionals in the field, including Michelle Ngai and Zhi-Ming Ding. These collaborations have enhanced the research and development of innovative therapeutic solutions.
Conclusion
Mark Majewski's contributions to RNAi therapeutics exemplify the impact of innovative research in biotechnology. His work not only advances scientific understanding but also holds promise for improving patient outcomes in various diseases.